2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

salvaged with either surgery or additional radiation and
have no evidence as yet of subsequent recurrence. 24 However,
the time to recurrence in this group is quite long. Most
data from patients who receive surgery demonstrate the
majority of local recurrences within 2 to 3 years of treatment.
Yet in this group, the mean interval is 52 months.
This highlights the need for continued close surveillance of
these patients, many years out from treatment. There is
interest in studying nonoperative management in Europe
and the United States, particularly in the low-lying tumors
that would require an abdominoperineal resection and permanent
colostomy.
Finally, tailored therapy may come in the way of selective
Author’s Disclosure of Potential Conflicts of Interest
Author
Karyn A. Goodman*
*No relevant relationships to disclose.
Employment or
Leadership
Positions
Consultant or
Advisory Role
1. Douglass HO Jr, Moertel CG, Mayer RJ, et al. Survival after postoperative
combination treatment of rectal cancer. N Engl J Med. 1986;315:1294-
1295.
2. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant
therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709-715.
3. O’Connell MJ, Martenson JA, Weiand HS, et al. Improving adjuvant
therapy for rectal cancer by combining protracted-infusion fluorouracil with
radiation therapy after curative surgery. N Engl J Med. 1994;331:502-507.
4. NIH consensus conference. Adjuvant therapy for patients with colon and
rectal cancer. JAMA. 1990;264:1444-1450.
5. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy
combined with total mesorectal excision for resectable rectal cancer.
N Engl J Med. 2001;345:638-646.
6. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy
versus selective postoperative chemoradiotherapy in patients with
rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised
trial. Lancet. 2009;373:811-820.
7. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and
without surgery in patients with locally advanced squamous cell carcinoma of
the esophagus. J Clin Oncol. 2005;23:2310-2317.
8. Bosset JF, Calais G, Mineur L, et al. Enhanced tumorocidal effect of
chemotherapy with preoperative radiotherapy for rectal cancer: preliminary
results-EORTC 22921. J Clin Oncol. 2005;23:5620-5627.
9. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with
or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers:
results of FFCD 9203. J Clin Oncol. 2006;24:4620-4625.
10. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil,
and leucovorin as adjuvant treatment for colon cancer. N Engl J Med.
2004;350:2343-2351.
11. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of
tumor regression after preoperative chemoradiotherapy for rectal cancer.
J Clin Oncol. 2005;23:8688-8696.
12. Janjan NA, Crane C, Feig BW, et al. Improved overall survival among
responders to preoperative chemoradiation for locally advanced rectal cancer.
Am J Clin Oncol. 2001;24:107-112.
13. Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, et al. A pathologic
complete response to preoperative chemoradiation is associated with lower
local recurrence and improved survival in rectal cancer patients treated by
mesorectal excision. Dis Colon Rectum. 2003;46:298-304.
14. Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance
therapy for patients who have a good response to induction
chemotherapy. In the near future, we will see the opening of
the PROSPECT trial: a large phase III randomized trial of
no radiotherapy for patients with good response to induction
chemotherapy. This study will accrue 1,000 patients to
determine if preoperative folinic acid, 5-FU, and oxaliplatin
(FOLFOX) is equivalent to standard preoperative chemoradiation.
This study is based on excellent outcomes in a pilot
study of 30 patients who received preoperative FOLFOX and
bevacizumab and had a 27% pCR rate. 25 The PROSPECT
trial is large enough to allow for a better understanding
of prognostic and predictive factors to help identify which
patients benefit from different therapeutic approaches.
Stock
Ownership Honoraria
REFERENCES
Research
Funding
Expert
Testimony
Other
Remuneration
of extent of rectal cancer response to preoperative radiation and chemotherapy.
Ann Surg. 2002;236:75-81.
15. Vecchio FM, Valentini V, Minsky B D, et al. The relationship of
pathologic tumor regression grade (TRG) and outcomes after preoperative
therapy in rectal cancer. Int J Radiat Oncol Biol Phys. 2005;62:752-760.
16. Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome
following preoperative combined modality therapy and total mesorectal
excision of locally advanced rectal cancer. Ann Surg. 2005;241:829-836.
17. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two
neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer:
results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol.
2010;28:1638-1644.
18. Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to
preoperative chemoradiation with or without oxaliplatin in locally advanced
rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
J Clin Oncol. 2011;29:2773-2780.
19. Roh MS, Yothers GA, O’Connell MJ, et al. The impact of capecitabine
and oxaliplatin in the preoperative multimodality treatment in patients with
carcinoma of the rectum: NSABP R-04. J Clin Oncol. 2011;29 (suppl 15; abstr
3503).
20. Roedel C, Becker H, Fietkau R, et al. Preoperative chemoradiotherapy
and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus
5-fluorouracil alone in locally advanced rectal cancer: First results of the
German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol. 2011;29
(suppl 15; abstr 3505).
21. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage
and treatment on survival and relapse in adjuvant rectal cancer: a pooled
analysis. J Clin Oncol. 2004;22:1785-1796.
22. Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for
predicting local recurrence, distant metastases, and overall survival for
patients with locally advanced rectal cancer on the basis of European
randomized clinical trials. J Clin Oncol. 2011;29:3163-3172.
23. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol.
2008;47:20-31.
24. Habr-Gama A, Perez RO, Proscurshim I, et al. Patterns of failure and
survival for nonoperative treatment of stage c0 distal rectal cancer following
neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006;10:1319-
1328.
25. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant FOLFOX-bev,
without radiation, for locally advanced rectal cancer. J Clin Oncol. 2010;28
(suppl 15; abstr 3511).
221